Next Article in Journal
Computerized Full-Color Assessment for Distinguishing Color Vision Deficiency
Previous Article in Journal
The Effect of Lumen-Apposing Metal Stent (LAMS) in Acute Cholecystitis Unfit for Surgery: Good Tidings
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Analysis of the Structural Characteristics and Psychometric Properties of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): A Systematic Review and Meta-Analysis

by
Marta María Córdoba-Peláez
1,
Guadalupe Molina-Torres
1,*,
Anna Rutkowska
2,
Sebastian Rutkowski
2 and
Jacobo Á. Rubio-Arias
3
1
Department of Nursing, Physiotherapy and Medicine, Faculty of Health Sciences, University of Almería, 04120 Almería, Spain
2
Department of Physical Education and Physiotherapy, Opole University of Technology, 45-758 Opole, Poland
3
Department of Education, Health Research Center, University of Almeria, 04120 Almería, Spain
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(22), 2836; https://doi.org/10.3390/diagnostics15222836 (registering DOI)
Submission received: 10 October 2025 / Revised: 4 November 2025 / Accepted: 5 November 2025 / Published: 9 November 2025
(This article belongs to the Section Clinical Diagnosis and Prognosis)

Abstract

Background: The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15) is a questionnaire designed to assess Sexual Dysfunction symptoms in multiple sclerosis patients; its first version was created in English and has been validated in 7 other languages. Objectives: The aim of the present study was to analyze the structural characteristics and psychometric properties of the different versions of the MSISQ-15. Methods: An analysis of the different versions of this questionnaire was carried out. The quality of the evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. A systematic review was carried out in different databases, such as PubMed, SCOPUS, Web of Science, Dialnet, ScienceDirect, and CINAHL. The following selection criteria were considered: studies that included cross-cultural validation of the MSISQ-15, studies with a sample of the population with multiple sclerosis and suffering from sexual dysfunction, studies that presented psychometric properties with total and/or domain scores of the MSISQ-15, and studies with a sample of the population over 18 years of age. Studies that used the MSISQ-15 as an outcome measure or to validate another instrument, and studies with inconclusive results, were excluded. Results: A total of seven studies were analyzed with regard to structural characteristics and psychometric properties, such as reliability, internal consistency, construct validity, and criterion validity. Conclusions: The different versions of the MSISQ-15 are valid for use in the Polish, German, Italian, French, Turkish, Greek, and Spanish populations, and it will be necessary to adapt the questionnaire to other languages for use with patients with multiple sclerosis in other countries.

1. Introduction

Normal sexual function depends on several factors, including neurological factors. Therefore, sexual dysfunction (SD) is one of the most common manifestations of disorders affecting the central or peripheral nervous system, including multiple sclerosis (MS) [1,2], a chronic, autoimmune, and neurodegenerative disease that affects the central nervous system, deteriorating the white matter in the brain and spinal cord. This disease is mainly characterized by crises of neurological dysfunction, after which a worsening of the neurological capacities of the patients occurs [3,4], affecting sexual function in 40–80% of women and 50–90% of men with MS [5,6,7,8].
In this sense, the processing of sexual stimuli can be altered in neurological disorders, which can prevent arousal, influence desire, reduce genital congestion, and even affect the patient’s sexual life and urinary continence [9]. Furthermore, the most common sexual dysfunctions (SD) in men with MS are erectile dysfunction, ejaculatory dysfunction and/or orgasmic dysfunction, reduced libido, and anorgasmia. On the other hand, the most frequently described SD in women is reduced libido and difficulty in reaching orgasm, reduced tactile sensations originating in the thigh and genital regions, and vaginal dryness with consequent dyspareunia [10,11].
A relationship has been described between psychological symptoms such as depression and anxiety and SD in patients with MS [12], which affects their quality of life [13]. Therefore, precise assessment instruments are needed that can help improve the therapeutic approach to this disease. For this, it is necessary to use patient-reported outcome measures (PROMs) that provide very valuable information, allowing the impact of subjective aspects of the pathology on the patient to be assessed, such as the impact on their quality of life, as this will influence clinical decision-making and the evaluation of the effectiveness of the treatment [14]. Thus, self-reported questionnaires play a key role.
In MS, it is more common to use specific questionnaires for the evaluation and classification of some of the most common signs and symptoms of people with MS. Some of these questionnaires include aspects of fatigue (Fatigue Impact Scale, FIS) [15], quality of life (Multiple Sclerosis Quality of Life 54, MSQoL-54) [16], and physical and psychological impact of the disease (Multiple Sclerosis Impact Scale, MSIS-29) [17].
The MS Intimacy and Sexuality Questionnaire is a questionnaire designed to assess SD symptoms in MS patients. Its first version was created in English by Dr. Foley and colleagues, who designed the tool to capture the multidimensional impact of MS on sexual function [18]. Since its initial development, the MSISQ-15 has been cross-culturally adapted and validated in seven additional languages: Polish, German, Italian, French, Turkish, Greek, and Spanish [19,20,21,22,23,24,25]. The MSISQ-15 divides SD into three dimensions: primary, resulting from neurological system function (questions 8, 12, 13, 14, 15); secondary, resulting from side effects of MS (questions 1, 2, 3, 4, 5); and tertiary, resulting from psychological, emotional, social, and cultural elements (questions 6, 7, 9, 10, 11). Patients rate each item with a Likert scale, which ranges from 1 (never) to 5 (always) [20].

2. Objectives

In order to improve future versions in other languages, it would be necessary to consider the structural characteristics and psychometric properties used in the versions already published. Therefore, the objective of this study was to analyze the structural characteristics and psychometric properties of the different language versions of the MSISQ-15, as well as the methodological quality, the quality of the evidence, and the criteria used, for good measurement properties.

3. Materials and Methods

3.1. Design and Protocol

A systematic review was conducted, encompassing articles published up to 27 October 2024, and registered in the PROSPERO database (PROSPERO ID: CRD42022344931), in accordance with the PRISMA statement [26] (see in Supplementary Materials) and the COSMIN guidelines [27].

3.2. Eligibility Criteria, Information Sources, and Search Strategy

The search was performed in the PubMed, SCOPUS, Web of Science, Dialnet, ScienceDirect, and CINAHL databases. The following MeSH terms were included with the Boolean operators AND/OR: “Multiple Sclerosis Intimacy and Sexuality Questionnaire” AND “sexual function” (“Sexual Dysfunction, Multiple Sclerosis” [Mesh]) OR “sexual function” [Title/Abstract]) AND “Surveys and Questionnaires” [Mesh] AND “Validation” [Title/Abstract] OR “Pelvic Floor Disorders” [Mesh]).
For this review, studies were included if they met the following criteria: they conducted cross-cultural validation of the MSISQ-15; involved adult participants (aged 18 or older) with multiple sclerosis who experience sexual dysfunction; and reported psychometric data for total and/or domain-specific scores of the MSISQ-15. Studies were excluded if the MSISQ-15 was only employed as an outcome measure, used to validate another instrument, or if the findings were inconclusive.

3.3. Study Selection

Records from various databases were imported into the Rayyan platform [28]. Initially, duplicate entries were removed, and then two independent reviewers (MMCP and ISH) screened the remaining records based on titles and abstracts. In cases of disagreement, a third reviewer (GMT) resolved the conflict. The studies that were ultimately selected were retrieved in full text for detailed content analysis and to determine their eligibility for inclusion in this review.

3.4. Data Extraction and Assessment of Risk of Bias

To collect information on the structural features and psychometric properties of each MSISQ-15 version, a detailed analysis of the different questionnaire adaptations was conducted. The methodological quality of each version was assessed using the risk-of-bias checklist from the COSMIN (Consensus-based Standards for the selection of health Measurement Instruments) guidelines, which are designed to support the selection of high-quality PROMs for both research and clinical practice [27,29].
For each version, the extracted structural characteristics included: title, year of publication, language/version, target population, sample size, age, sex, participant characteristics, setting, geographic location, pilot phase sample size, and number of participants per item. The psychometric properties evaluated were test–retest reliability, internal consistency, construct validity, and criterion validity. Each measurement property was then assessed individually according to the updated criteria for good measurement properties and rated as sufficient (+), insufficient (−), or indeterminate (?) [29,30].

3.5. Data Synthesis

Finally, the evidence was summarized, and the quality of the evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach [29].

4. Results

4.1. Study Selection Results

Following the initial search in the PubMed, Scopus, and Web of Science databases, as shown in the flow chart of the selected studies (Figure 1), a total of 63 results were found. Excluding duplicates and after selecting articles by title and abstract, 48 were selected, of which 36 were excluded, and 12 full-text articles were selected for eligibility, of which five of them did not meet the inclusion criteria, did not present the results conclusively, did not include a validation phase, or were not a cross-cultural adaptation of the MSISQ-15.
Finally, a total of seven versions, adapted and validated to languages other than the original, were selected: Polish, Dutch, Italian, French, Turkish, Greek, and Spanish. Then, the structural characteristics of each one of them were analyzed (see Table 1).

4.2. Study Characteristics

Table 2 summarizes data corresponding to the psychometric properties of each questionnaire: test–retest, internal consistency, construct validity, and criterion validity.

4.3. Risk of Bias of Included Studies

4.3.1. Structural Validity

None of the versions included an analysis of the structural validity of the MSISQ-15.

4.3.2. Internal Consistency

Of the seven versions of the questionnaire, all included an internal consistency analysis using Cronbach’s alpha. All Cronbach’s alpha values were greater than 0.7, indicating a good internal consistency [29]. The highest value of Cronbach’s alpha was that of the Polish version, with a Cronbach’s α = 0.93 [23], while the lowest was the Italian version, α = 0.75 [21].

4.3.3. Test–Retest Reliability

The intraclass correlation coefficient (ICC) was used in five of the six versions of the questionnaire, which calculates the test–retest reliability [19,20,21,22,23]. Only the Greek version [24] used Pearson’s correlation coefficient, while the Spanish version did not calculate the ICC [25]. All ICC values were greater than 0.7 and were, therefore, considered to have an acceptable reliability [31]. The highest ICC was found in the Turkish version, which was between 0.992 and 0.998 [19], and the lowest was the German version with a value of 0.88 [22]. The Italian version did not specifically define its ICC; it only specified that it was greater than 0.7 [21].

4.3.4. Responsiveness

None of the versions included this measurement, which is the ability of a PROM to detect changes over time in the construct to be measured [27].

4.3.5. Methodological Quality

Methodological quality was assessed according to the criteria of the COSMIN guidelines [27]. The quality of each study on a PROM must be assessed separately and can be classified as: very good, adequate, doubtful, or inadequate quality [27].

4.3.6. Quality of Evidence

The GRADE system was used to assess the quality of the evidence [32], which considers the risk of bias, inconsistency, imprecision, and indirectness (see Table 3).

4.4. Synthesis of Results

The meta-analysis was performed with the 7 articles included in this review, as all the versions provided a Cronbach’s α value. The results indicate a cumulative Cronbach alpha coefficient of 0.893 (95%CI: 0.845–0.941; SE: 0.0245; Z: 36.4; p < 0.001) with a high heterogeneity (I2: 98.1%) (See Figure 2).
The evaluation of publication bias through the Fail-safe N method yielded a value of 672.720 (p < 0.001), and Egger’s regression showed a value of −6.361 (p < 0.001). These results suggest a high consistency in the reliability of the measurements analyzed, despite the presence of significant heterogeneity between the studies (see Figure 3).

5. Conclusions

This study aimed to carry out an analysis of the structural characteristics and psychometric properties of the MSISQ-15 questionnaire in all its versions, allowing them to be compared with each other and with the original version [18]. A total of seven versions of the MSISQ-15 were included: Polish [23], Dutch [22], Italian [21], French [20], Turkish [19], Greek [24], and Spanish [25].
In the validation phase, the version that included more patients was the Polish one with 227 patients [23]. On the contrary, the version that included fewer patients was the Italian one, with 67 [21]. The rest of the versions included: 208 patients in the Spanish version [25], 130 in the Turkish [19], 127 in the Greek [24], 102 in the Dutch [22], and 98 in the French [20] versions. The number of patients included in the cross-cultural adaptation was much lower than that of the original version, which included 6300 patients [18]. According to the COSMIN guidelines, a version of the MSISQ-15 questionnaire, which consists of 15 items, must include more than 150 participants to be rated as excellent. Only the Polish and Spanish versions [23,25] were rated as excellent, while the rest of the versions had more than 5 subjects per item, except for the Italian version [21], which included fewer than 5 subjects per item.
None of the versions considered structural validity, not even the original one. Internal consistency was included in all versions. However, none of them reached the values of the original version [18], which obtained a high internal consistency. Reliability was calculated in all versions using the ICC [19,20,21,22,23,24], except for the Spanish one, which was not calculated [25]. Nevertheless, in the remaining versions, it exceeded the value 0.7, or acceptable. Measurement error, which is important in decision-making and in the evaluation of change, was only calculated in the German, French, and Turkish versions [19,20,22]. Hypothesis testing was calculated in the German, Greek, Turkish, and Spanish versions [19,22,24,25], indicating a high risk of bias in the versions that did not present it [20,21,23]. Responsiveness was not calculated in any version due to the short follow-up that they adopted to ensure adequate test–retest analyses with no clinical interventions between the two measurements, and to minimize possible symptom changes.

Strengths and Limitations of the Study

Regarding the results of the meta-analysis, the results of the first meta-analysis indicated that there was a high internal consistency in the questionnaire measures, with a mean Cronbach’s α of 0.89. However, a highly significant heterogeneity was observed, suggesting that there are differences in the measurements beyond random variability. Furthermore, evidence of publication bias was found using a funnel plot analysis, and confirmed using Egger’s test, which may be due to studies with negative and non-significant results, or those that do not support their preconceived theories, not being published or being incompletely reported.
In conclusion, the MSISQ-15 questionnaire has been adapted into 7 languages, each of them with good measurement properties, mostly rated as having a high and moderate methodological quality considering the COSMIN guidelines. The different versions of the MSISQ-15 are valid for use in the Polish, German, Italian, French, Turkish, Greek, and Spanish populations, and it will be necessary to adapt the questionnaire into other languages for use in patients with multiple sclerosis in other countries, considering the structural characteristics compiled in this review.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics15222836/s1, PRISMA 2020 Checklist. Reference [33] was cited in Supplementary Materials.

Author Contributions

M.M.C.-P. and G.M.-T.: conceptualisation, methodology, data curation, writing—original draft, writing—review and editing; J.Á.R.-A.: methodology, formal analysis, review and editing, and supervision; A.R. and S.R.: methodology, data curation. All authors have read and agreed to the published version of the manuscript.

Funding

This article is part of the ADVICE project (Project PID2021-123447OA-I00), funded by MCIN/AEI/10.13039/501100011033 and by FEDER Una manera de hacer Europa.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Frohman, E.M. Sexual Dysfunction in Neurologic Disease. Clin. Neuropharmacol. 2002, 25, 126–132. [Google Scholar] [CrossRef]
  2. Mosalanejad, F.; Afrasiabifar, A.; Zoladl, M. Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: A randomized controlled trial. Clin. Rehabil. 2018, 32, 1340–1347. [Google Scholar] [CrossRef]
  3. Quarto, G.; Autorino, R.; Gallo, A.; de Sio, M.; D’Armiento, M.; Perdonà, S.; Damiano, R. Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int. Urogynecol. J. 2007, 18, 189–194. [Google Scholar] [CrossRef]
  4. Katz Sand, I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr. Opin. Neurol. 2015, 28, 193–205. [Google Scholar] [CrossRef]
  5. Ashtari, F.; Rezvani, R.; Afshar, H. Sexual dysfunction in women with multiple sclerosis: Dimensions and contributory factors. J. Res. Med. Sci. 2014, 19, 228–233. [Google Scholar]
  6. Tepavcevic, D.; Kostic, J.; Basuroski, I.; Stojsavljevic, N.; Pekmezovic, T.; Drulovic, J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult. Scler. J. 2008, 14, 1131–1136. [Google Scholar] [CrossRef]
  7. Zorzon, M.; Zivadinov, R.; Monti Bragadin, L.; Moretti, R.; de Masi, R.; Nasuelli, D.; Cazzato, G. Sexual dysfunction in multiple sclerosis: A 2-year follow-up study. J. Neurol. Sci. 2001, 187, 1–5. [Google Scholar] [CrossRef]
  8. Zorzon, M.; Zivadinov, R.; Bosco, A.; Bragadin, L.M.; Moretti, R.; Bonfigli, L.; Morassi, P.; Iona, L.G.; Cazzato, G. Sexual dysfunction in multiple sderosis: A case-control study. 1. Frequency and comparison of groups. Mult. Scler. J. 1999, 5, 418–427. [Google Scholar] [CrossRef]
  9. Rees, P.M.; Fowler, C.J.; Maas, C.P. Sexual function in men and women with neurological disorders. Lancet 2007, 369, 512–525. [Google Scholar] [CrossRef]
  10. Borello-France, D.; Leng, W.; O’Leary, M.; Xavier, M.; Erickson, J.; Chancellor, M.B.; Cannon, T.W. Bladder and sexual function among women with multiple sclerosis. Mult. Scler. J. 2004, 10, 455–461. [Google Scholar] [CrossRef]
  11. Redelman, M.J. Sexual difficulties for persons with multiple sclerosis in New South Wales, Australia. Int. J. Rehabil. Res. 2009, 32, 337–347. [Google Scholar] [CrossRef]
  12. Zivadinov, R.; Zorzon, M.; Bosco, A.; Bragadin, L.M.; Moretti, R.; Bonfigli, L.; Iona, L.G.; Cazzato, G. Sexual dysfunction in multiple sderosis: II. Correlation analysis. Mult. Scler. J. 1999, 5, 428–431. [Google Scholar] [CrossRef]
  13. Calabrò, R.S.; Cacciola, A.; Bruschetta, D.; Milardi, D.; Quattrini, F.; Sciarrone, F.; la Rosa, G.; Bramanti, P.; Anastasi, G. Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? Brain Behav. 2019, 9, e01389. [Google Scholar] [CrossRef]
  14. Kyte, D.G.; Calvert, M.; van der Wees, P.J.; ten Hove, R.; Tolan, S.; Hill, J.C. An introduction to patient-reported outcome measures (PROMs) in physiotherapy. Physiotherapy 2015, 101, 119–125. [Google Scholar] [CrossRef] [PubMed]
  15. Benito-León, J.; Martínez-Martín, P.; Frades, B.; Martínez-Ginés, M.L.; de Andrés, C.; Meca-Lallana, J.E.; Antigüedad, A.; Huete-Antón, B.; Rodríguez-García, E.; Ruiz-Martínez, J. Impact of fatigue in multiple sclerosis: The Fatigue Impact Scale for Daily Use (D-FIS). Mult. Scler. J. 2007, 13, 645–651. [Google Scholar] [CrossRef]
  16. Vickrey, B.G.; Hays, R.D.; Harooni, R.; Myers, L.W.; Ellison, G.W. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 1995, 4, 187–206. [Google Scholar] [CrossRef]
  17. Hobart, J. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001, 124, 962–973. [Google Scholar] [CrossRef]
  18. Foley, F.W.; Zemon, V.; Campagnolo, D.; Marrie, R.A.; Cutter, G.; Tyry, T.; Beier, M.; Farrell, E.; Vollmer, T.; Schairer, L. The Multiple Sclerosis Intimacy and Sexuality Questionnaire—Re-validation and development of a 15-item version with a large US sample. Mult. Scler. J. 2013, 19, 1197–1203. [Google Scholar] [CrossRef]
  19. Dogan, H.; Abakay, H.; Tekin, G.; Saçmaci, H.; Goksuluk, M.B.; Ozengin, N. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ): Validation of the Turkish version in patient with multiple sclerosis. Mult. Scler. Relat. Disord. 2022, 64, 103965. [Google Scholar] [CrossRef]
  20. Lefebvre, S.; Houot, M.; Delgadillo, D.; Cantal Dupart, M.D.; Varin, D.; Papeix, C.; Sevin, M.; Bourmaleau, J.; Laigle-Donadey, F.; Jovic, L. Validation of the French version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire 15 Tools which help nurse for assessing the effect of perceived multiple sclerosis symptoms on sexual activity and satisfaction. Nurs. Open 2023, 10, 570–578. [Google Scholar] [CrossRef]
  21. Monti, M.; Marquez, M.A.; Berardi, A.; Tofani, M.; Valente, D.; Galeoto, G. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Validation of the Italian version for individuals with spinal cord injury. Spinal Cord. 2020, 58, 1128–1133. [Google Scholar] [CrossRef] [PubMed]
  22. Noordhoff, T.C.; Scheepe, J.R.; ’t Hoen, L.A.; Sluis, T.A.R.; Blok, B.F.M. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Validation of the Dutch version in patients with multiple sclerosis and spinal cord injury. Neurourol. Urodyn. 2018, 37, 2867–2874. [Google Scholar] [CrossRef]
  23. Przydacz, M.; Golabek, T.; Dudek, P.; Chlosta, P. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Translation, adaptation and validation of the Polish version for patients with multiple sclerosis and spinal cord injury. BMC Neurol. 2021, 21, 103. [Google Scholar] [CrossRef]
  24. Tzitzika, M.; Daoultzis, C.C.; Konstantinidis, C.; Kordoutis, P. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Validation and Cross-cultural Adaptation of the Greek Version in MS Patients. Sex. Disabil. 2021, 39, 495–506. [Google Scholar] [CrossRef]
  25. Ríos, A.E.; Cabañero-Martínez, M.J.; Escribano, S.; Foley, F.; García-Sanjuán, S. Validation and cross-cultural adaptation of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-15 (MSISQ-15) into Spanish. PeerJ 2023, 11, e15138. [Google Scholar] [CrossRef]
  26. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef]
  27. Mokkink, L.B.; Prinsen, C.A.C.; Bouter, L.M.; Vet HCWde Terwee, C.B. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. Braz. J. Phys. Ther. 2016, 20, 105–113. [Google Scholar] [CrossRef]
  28. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef]
  29. Prinsen, C.A.C.; Mokkink, L.B.; Bouter, L.M.; Alonso, J.; Patrick, D.L.; de Vet, H.C.W.; Terwee, C.B. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual. Life Res. 2018, 27, 1147–1157. [Google Scholar] [CrossRef]
  30. Prinsen, C.A.C.; Vohra, S.; Rose, M.R.; Boers, M.; Tugwell, P.; Clarke, M.; Williamson, P.R.; Terwee, C.B. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set”—A practical guideline. Trials 2016, 17, 449. [Google Scholar] [CrossRef]
  31. Terwee, C.B.; Bot, S.D.M.; de Boer, M.R.; van der Windt, D.A.W.M.; Knol, D.L.; Dekker, J.; Bouter, L.M.; de Vet, H.C.W. Quality criteria were proposed for measurement properties of health status questionnaires. J. Clin. Epidemiol. 2007, 60, 34–42. [Google Scholar] [CrossRef]
  32. Aguayo-Albasini, J.L.; Flores-Pastor, B.; Soria-Aledo, V. Sistema GRADE: Clasificación de la calidad de la evidencia y graduación de la fuerza de la recomendación. Cir. Esp. 2014, 92, 82–88. [Google Scholar] [CrossRef]
  33. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
Figure 1. Flowchart for the selection of studies based on PRISMA.
Figure 1. Flowchart for the selection of studies based on PRISMA.
Diagnostics 15 02836 g001
Figure 2. Forest plot with the Cronbach’s α coefficients of the MSISQ-15 [19,20,21,22,23,24,25].
Figure 2. Forest plot with the Cronbach’s α coefficients of the MSISQ-15 [19,20,21,22,23,24,25].
Diagnostics 15 02836 g002
Figure 3. Funnel Plot with Cronbach’s α coefficients of the MSISQ-15.
Figure 3. Funnel Plot with Cronbach’s α coefficients of the MSISQ-15.
Diagnostics 15 02836 g003
Table 1. Structural characteristics of the questionnaires.
Table 1. Structural characteristics of the questionnaires.
Questionnaire/Author, Year of Publication/
Version
Population/
Sample Size, Age, Group
Affected and Control Group Setting/
Geographical
Location
Target Population and Time Since Diagnosis Number of Subjects–Phase
Pilotage
Number of Subjects
Per Item
The Multiple Sclerosis
Intimacy and Sexuality
Questionnaire (MSISQ-15): Validation of the Dutch version in patients with multiple sclerosis and spinal cord injury/Noordhoff et al., 2018/Dutch version [22]
n = 102
SCI: 53
MS: 49
Age:
SCI: 41.3 ± 11.9
MS: 46.0 ± 10.1
Sex:
SCI: Men: 12 ± 22.6
Women: 41 ± 77.4
MS: Men: 41 (83.7)
Women: 8 (16.3)
AG: 102
CG: 50
NRSCI and MS
SCI: 10.1 ± 7.5
MS: 13.1 ± 11.7
total: 6.8
SCI: 3.53
MS: 3.29
The Multiple Sclerosis Intimacy and Sexuality
Questionnaire (MSISQ-15): validation of the Italian
version for individuals
with spinal cord injury/Monti et al., 2020/
Italian version [21]
n = 65
Age:
40.4 ± 11.9
Sex:
Men: 47 ± 72.3
Women: 27 ± 27.7
La Sapienza University of Rome and the
Rehabilitation and
Outcome Measures
Assessment Association
SCI 4.33
The Multiple Sclerosis Intimacy and Sexuality
Questionnaire (MSISQ-15): Validation and
Cross-cultural Adaptation
of the Greek Version in MS Patients/Tzitzika et al., 2021/Greek version [24]
n = 127
Age:
MS: 45.57 ± 11.13
CG: 53.02 ± 9.36
Sex:
MS: Men: 35
Women: 33
CG: Men: 34
Women: 25
AG: 68
CG: 59
Urology Department of the National Rehabilitation Centre of AthensMS 8.46
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15):
translation, adaptation, and validation of the Polish
version for patients with multiple sclerosis and spinal cord injury/Przydacz et al., 2021/Polish version [23]
n = 227
SCI: 110
MS: 117
Age:
SCI: 39.2 ± 9.9
MS: 44.2 ± 9.4
Sex:
SCI: Men: 98 (89.1%)
Women: 12 (10.9%)
MS: Men: 35 (29.9%)
Women: 82 (70.1%)
CG not includedDepartment of
Urology of the Jagiellonian University Medical
College,
Krakow, Poland
SCI and MS
SCI: 12.9 ± 10.9
MS: 9.2 ± 8.3
299 test phasetotal: 15.33
SCI: 7.33
MS: 7.8
Validation of the French version of the Multiple
Sclerosis Intimacy and Sexuality Questionnaire 15 Tools which help nurses assess the effect of perceived multiple sclerosis symptoms on sexual
activity and satisfaction/Lefebvre et al., 2023/
French version [20]
n = 98
Age:
44.31 ± 11.33
Sex:
Men: 30
Women: 68
AG: 51
CG: 51
Neurology department at the La Pitié Salpêtrière
hospital in Paris, France
MS 6.53
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ): Validation of the Turkish version in patients with multiple sclerosis/Dogan et al., 2022/Turkish version [19]n = 130
Age:
41.77 ± 10.84
Sex:
Women 100%
AG:130Neurology department of a university hospitalMS308.66
Validation and
cross-cultural adaptation
of Multiple Sclerosis
Intimacy and Sexuality Questionnaire-15 (MSISQ-15) into Spanish/Ríos et al., 2023/Spanish version [25]
n = 208
Age:
44.59 ± 9.788
Sex:
Men: 73
Women: 135
CG not
included
Multiple sclerosis
associations in Spain
MS
11.685 ± 8.5052
13.86
SCI: Spinal Cord Injury, MS: Multiple Sclerosis, AG: Affected Group, CG: Control Group.
Table 2. Psychometric properties of the questionnaires.
Table 2. Psychometric properties of the questionnaires.
Author/VersionTest–Retest
Reliability
Internal
Consistency
Construct Validity
Noordhoff et al., 2018/
Dutch version [22]
TS 0.88 (0.79–0.93)
1D 0.90 (0.84–0.94)
2D 0.75 (0.60–0.85)
3D 0.86 (0.77–0.92)
Cronbach’s α = 0.90Indeterminate
Monti et al., 2020/
Italian version [21]
NECronbach’s α = 0.75MSISQ-15–SF-12 Mental health (r) Pearson: −0.360
MSISQ-15–SF-12 Physical health (r) Pearson: −0.219
MSISQ-15–SCIM SR Self-care (r) Pearson: −0.033
MSISQ-15–SCIM SR Management of respiration and sphincter (r) Pearson: −0.036
MSISQ-15–SCIM SR Mobility (r) Pearson: −0.003
MSISQ-15–Total SCIM SR: −0.028
Tzitzika et al., 2021/
Greek version [24]
TS 0.83
1D 0.84
2D 0.77
3D 0.86
Cronbach’s α = 0.83MSISQ-15–IIEF (r): −0.57
MSISQ-15–FSFI (r): −0.60
Przydacz et al., 2021/
Polish version [23]
TS 0.91 (0.80–0.95)
1D 0.93 (0.82–0.97)
2D 0.78 (0.70–0.86)
3D 0.87 (0.79–0.93)
Cronbach’s α = 0.93MSISQ-15–IIEF-15 (r) Pearson Test phase: −0.487
MSISQ-15–IIEF-15 (r) Pearson Retest phase: −0.456
MSISQ-15–PISQ-31 (r) Pearson Test phase: −0.709
MSISQ-15–PISQ-31 (r) Pearson Retest phase: −0.688
Lefebvre et al., 2023/
French version [20]
TS 0.90 (0.63; 0.98)
1D 0.91 (0.65; 0.98)
2D 0.30 (−0.24; 0.76)
3D 0.93 (0.74; 0.98)
Cronbach’s α = 0.90Indeterminate
Dogan et al., 2022/
Turkish version [19]
TS 0.998
1D 0.992
2D 0.990
3D 0.994
Cronbach’s α = 0.992MSISQ-15–MSQOL-54 (r) Pearson correlation
1D: −0.647; 2D: −0.706; 3D: −0.703; Total: −0.763
MSISQ-15–FSFI (r) Pearson correlation
1D: −0.776; 2D: −0.594; 3D: −0.655; Total: −0.754
MSISQ-15–PSIQ-12 (r) Pearson correlation
1D: −0.741; 2D: −0.678; 3D: −0.782; Total: −0.798
Ríos et al., 2023/Spanish version [25]NECronbach’s α = 0.89MSISQ-15–FSH (rho) Spearman
1D: (−0.53); 2D: (−0.31); 3D: (−0.42); Total (−0.52)
MSISQ-15–FSM-2 (rho) Spearman
1D: (−0.65); 2D: (−0.27); 3D: (−0.32); Total (−0.55)
MSISQ-15–EAD-13 (rho) Spearman
1D: (−0.14); 2D: (−0.10); 3D: (−0.08); Total (−0.14)
MSISQ-15–MusiQol (rho) Spearman
1D: (−0.25); 2D: (−0.35); 3D: (−0.38); Total (−0.039)
TS: total score, 1D: primary domain, 2D: secondary domain, 3D: tertiary domain, NE: not evaluable.
Table 3. Analysis of the rating of the psychometric properties, methodological quality, and quality of evidence.
Table 3. Analysis of the rating of the psychometric properties, methodological quality, and quality of evidence.
PROMVersionStructural Validity
(Rating)
Internal Consistency
(Rating)
Reliability
(Rating)
Measurement
Error
(Rating)
Hypotheses Testing
(Rating)
Responsiveness
(Rating)
Przydacz. et al., 2021 [23]PolishNRSufficientSufficientNRNRNR
Methodological quality
Risk of bias
NRVery goodAdequateNRNRNR
Quality of evidenceNRHighModerateNRNRNR
Noordhoff et al., 2018 [22]DutchNRSufficientSufficientNESufficientNR
Methodological quality
Risk of bias
NRVery goodDoubtfulVery goodVery goodNR
Quality of evidenceNRModerateHighModerateModerateNR
Monti et al., 2020 [21]ItalianNRSufficientSufficientNRNRNR
Methodological quality
Risk of bias
NRVery goodDoubtfulNRNRNR
Quality of evidenceNRHighModerateNRNRNR
Lefebvre et al., 2023 [20]FrenchNRSufficientSufficientSufficientNRNR
Methodological quality
Risk of bias
NRVery goodAdequateAdequateNRNR
Quality of evidenceNRModerateModerateHighNRNR
Dogan et al., 2022 [19]TurkishNRSufficientSufficientNENENR
Methodological quality
Risk of bias
NRVery goodDoubtfulAdequateVery goodNR
Quality of evidenceNRHighHighModerateModerateNR
Tzitzika et al., 2021 [24]GreekNRSufficientSufficientNRSufficientNE
Methodological quality
Risk of bias
NRVery goodAdequateNRVery goodInadequate
Quality of evidenceNRHighModerateNRModerateModerate
Ríos et al., 2023 [25]SpanishNRAdequateNRNRNRNR
Methodological quality
Risk of bias
NRVery goodNRNRNRNR
Quality of evidenceNRModerateNRNRNRNR
NR: not reported; NE: not evaluable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Córdoba-Peláez, M.M.; Molina-Torres, G.; Rutkowska, A.; Rutkowski, S.; Rubio-Arias, J.Á. Analysis of the Structural Characteristics and Psychometric Properties of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): A Systematic Review and Meta-Analysis. Diagnostics 2025, 15, 2836. https://doi.org/10.3390/diagnostics15222836

AMA Style

Córdoba-Peláez MM, Molina-Torres G, Rutkowska A, Rutkowski S, Rubio-Arias JÁ. Analysis of the Structural Characteristics and Psychometric Properties of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): A Systematic Review and Meta-Analysis. Diagnostics. 2025; 15(22):2836. https://doi.org/10.3390/diagnostics15222836

Chicago/Turabian Style

Córdoba-Peláez, Marta María, Guadalupe Molina-Torres, Anna Rutkowska, Sebastian Rutkowski, and Jacobo Á. Rubio-Arias. 2025. "Analysis of the Structural Characteristics and Psychometric Properties of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): A Systematic Review and Meta-Analysis" Diagnostics 15, no. 22: 2836. https://doi.org/10.3390/diagnostics15222836

APA Style

Córdoba-Peláez, M. M., Molina-Torres, G., Rutkowska, A., Rutkowski, S., & Rubio-Arias, J. Á. (2025). Analysis of the Structural Characteristics and Psychometric Properties of the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): A Systematic Review and Meta-Analysis. Diagnostics, 15(22), 2836. https://doi.org/10.3390/diagnostics15222836

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop